<DOC>
	<DOCNO>NCT01872598</DOCNO>
	<brief_summary>The objective compare efficacy safety oral masitinib 3 4.5 mg/kg/day combination cholinesterase inhibitor and/or memantine placebo combination cholinesterase inhibitor and/or memantine patient mild-to-moderate Alzheimer 's disease .</brief_summary>
	<brief_title>A Phase 3 Study Evaluate Safety Efficacy Masitinib Patients With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description>Actual standard treatment mild moderately severe Alzheimer 's dementia include acetylcholinesterase inhibitor ( donepezil , rivastigmine galantamine ) NMDA receptor antagonist ( memantine moderate severe Alzheimer 's disease ) . These medication show effect cognitive non cognitive symptom pathology . However , efficacy remains limited may decrease time . There unmet medical need pathology . Based pre-clinical clinical study , masitinib ( AB1010 ) consider good candidate dose 3 4.5 mg/kg/day .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1 . Male female patient 2 . Age ≥ 50 year , weigh 49,9 kg Body Mass Index ( BMI ) &gt; 18 3 . Patient and/ caregiver able understand patient card follow patient card procedure case sign symptom severe neutropenia severe cutaneous toxicity , first 2 month 4 . Menopause ≥ 2 year female patient 5 . Patient dementia Alzheimer 's type , accord DSMIV criterion 6 . Patient probable Alzheimer ' disease accord NINCDSADRDA criterion 7 . MMSE ≥ 12 ≤ 25 baseline 8 . Patient treat minimum 6 month stable dose cholinesterase inhibitor ( rivastigmine ) baseline , and/or stable dose memantine minimum 6 month baseline , change foresee therapy throughout study 9 . Patient adequate organ function screen baseline : Absolute Neutrophils Count ( ANC ) ≥ 2 x 109/L Hemoglobin ≥ 10 g/dL Platelets ( PTL ) ≥ 100 x 109/L AST/ALT ≤ 2.5 ULN Bilirubin ≤ 1.5 ULN Albuminemia &gt; 1 x LLN Urea ≤ 1.5 x ULN Creatinin clearance &gt; 60 mL/min ( Cockcroft Gault formula ) Proteinuria &lt; 30 mg/dL dipstick ; case proteinuria ≥ 30mg/dL , 24 hour proteinuria &lt; 1.5g/24 hour 10 . Patient regular reliable caregiver . The designated caregiver must sufficiently familiar patient ( determined investigator ) provide accurate data . The caregiver must regular contact patient ( i.e. , average 10 hour per week ) , must able observe possible adverse event , must able oversee patient 's compliance study treatment report patient 's status must able accompany patient visit 11 . Patient , identify caregiver , applicable , patient surrogate able willing comply study visit procedure per protocol , understand , sign , date inform consent form screen visit prior protocolspecific procedure perform 12 . Male patient must agree use one method medically acceptable form contraception ( partner must also use one childbearing potential ) study 3 month last treatment intake . 1 . Patient cause dementia due Alzheimer 's disease , base specific examination include brain neuroimagery exam within last 6 month : Other central nervous condition cause progressive deficit memory cognition , e.g . cerebrovascular disease ( patient 4 microbleeds 2 lacunes MRI could enrol study ) , Parkinson 's disease , Huntington 's disease , brain tumor… Systemic condition know cause dementia , e.g. , hypothyroidism , untreated vitamin B12 folic acid deficiency , niacin deficiency , neurosyphilis , HIV infection… Substanceinduced dementia 2 . Patient Alzheimer disease severe form delusion delirium ( patient light mild form delusion delirium allow study 3 . Patient treat registered putative cognitive/memory enhancer disease modifier rivastigmine memantine . ( Patients take Ginkgo Biloba enrol provide take stable dose least 6 month 4 . Patient evidence psychosis and/or use antipsychotic drug screen , history significant psychiatric disorder 5 . Patient active current bacterial , viral ( include hepatitis B C , HIV , EBV , CMV , herpes zoster ) , fungal , mycobacterium , protozoan , infection 6 . Patient history infection require hospitalization within 2 week screen 7 . Patient present cardiac disorder define least one follow condition : Patient recent cardiac history ( within 6 month ) : Acute coronary syndrome Acute heart failure ( class III IV NYHA classification ) Significant ventricular arrhythmia ( persistent ventricular tachycardia , ventricular fibrillation , resuscitate sudden death ) Patient cardiac failure class III IV NYHA classification Patient severe conduction disorder prevent permanent pacing ( atrioventricular block 2 3 , sinoatrial block ) Syncope without know aetiology within 3 month Uncontrolled severe hypertension , accord judgment investigator , symptomatic hypertension 8 . Patient chronic diarrhea 9 . Patient present oedemas 10 . Patient co exist dermatological disease ( e.g . eczema , psoriasis ) history skin allergy 11 . Patient history poor compliance history drug/alcohol abuse , excessive alcohol beverage consumption would interfere ability comply study protocol , current past psychiatric disease might interfere ability comply study protocol give informed consent 12 . Patient life expectancy &lt; 1 year Previous medication : 13 . Patient treat investigational agent within 4 week screen</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Alzheimer</keyword>
	<keyword>dementia</keyword>
	<keyword>cognitive disease</keyword>
	<keyword>memory loss</keyword>
	<keyword>cerebrovascular disease</keyword>
</DOC>